Logo

American Heart Association

  2
  0


Final ID: Mo3109

Impact of Obstructive Sleep Apnea on In-Hospital Outcomes of Adults with Hypertrophic Cardiomyopathy

Abstract Body (Do not enter title and authors here): Background. Obstructive sleep apnea (OSA) has been reported in a sizable proportion of adults with hypertrophic cardiomyopathy (HCM) and has been associated with higher incidence of adverse outcomes including arrhythmias (atrial fibrillation, non-sustained ventricular tachycardia) and sudden cardiac death when untreated. We aimed to evaluate the impact of OSA on in-hospital outcomes of patients with HCM.
Methods. National Inpatient Sample 2016-2020 was queried to identify admissions for HCM patients with (HCM+OSA) and without (HCM-OSA) OSA. In-hospital outcomes were compared with use of logistic regression.
Results. From 2016-2020, 271,085 adults with HCM were admitted to hospital of whom 45,135 (16.6%) were identified to also have OSA. Age was similar between both groups. (Table) Comorbidities (diabetes, coronary artery disease, hyperlipidemia, and chronic kidney disease) were more prevalent among HCM+OSA [Table]. Additionally, HCM+OSA more often had the obstructive phenotype (43.8 vs. 42.87%, p<0.001), heart Failure with preserved ejection fraction (37.75 vs. 27.01%, p<0.001), and paroxysmal atrial fibrillation (24.65 vs. 19.76%, p<0.001) and more frequently underwent septal reduction therapy [surgical myectomy (2.61 vs. 2.09%) or alcohol septal ablation (0.94 vs. 0.76%), both p<0.001)]. In-hospital outcomes such as overall mortality, need for intensive care unit admission, mechanical ventilation, mechanical circulatory support and use of vasopressors did not differ among patients with HCM and with or without SH [Table].
Conclusion. In this study, 1 in ~6 adults with HCM admitted to hospital also had OSA. OSA in HCM was associated with higher prevalence of comorbid conditions and the obstructive phenotype and thus higher rates of septal reduction therapy. However, presence of OSA did not impact in-hospital outcomes of HCM in this study.
  • Roma, Nicholas  ( St. Luke's University Health Network , Bethlehem , Pennsylvania , United States )
  • Desai, Spandan  ( St. Luke's University Health Network , Bethlehem , Pennsylvania , United States )
  • Pattoli, Megan  ( St. Luke's University Health Network , Bethlehem , Pennsylvania , United States )
  • Magid, Lindsey  ( St. Luke's University Health Network , Bethlehem , Pennsylvania , United States )
  • Yellapu, Vikas  ( St.Luke's University Helath Network , Bethlehem , Pennsylvania , United States )
  • Shirani, Jamshid  ( St. Luke's University Health Network , Bethlehem , Pennsylvania , United States )
  • Author Disclosures:
    Nicholas Roma: DO NOT have relevant financial relationships | Spandan Desai: DO NOT have relevant financial relationships | Megan Pattoli: DO NOT have relevant financial relationships | Lindsey Magid: DO NOT have relevant financial relationships | Vikas Yellapu: No Answer | Jamshid Shirani: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Sleep and Cardiovascular Health: Implications and Outcomes

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts from these authors:
COVID-19 Impacted Septal Reduction Therapies in Hypertrophic Cardiomyopathy

Desai Spandan, Roma Nicholas, Pattoli Megan, Durkin Matthew, Shah Kashyap, Amaratunga Eluwana, Magid Lindsey, Yellapu Vikas, Shirani Jamshid

Comparative Characteristics and Outcomes of Primary Compared to Glycogen Storage Disease-Associated Hypertrophic Cardiomyopathy

Desai Spandan, Roma Nicholas, Pattoli Megan, Durkin Matthew, Henstenburg Brian, Magid Lindsey, Yellapu Vikas, Miller Luke, Shirani Jamshid

You have to be authorized to contact abstract author. Please, Login
Not Available